Safety and efficacy of unfractionated heparin vs. enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies

Author： Spinler S.A.   Inverso S.M.   Cohen M.   Goodman S.G.   Stringer K.A.   Antman E.M.   for the ESSENCE and TIMI IIB Investigators  

Publisher： Elsevier

ISSN： 1062-1458

Source： ACC Current Journal Review, Vol.12, Iss.5, 2003-09, pp. : 15-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes - Results from the thrombolysis in myocardial infarction (TIMI) 11B and efficacy and safety of subcutaneous enoxaparin in Non-Q-Wave coronary events (ESSENCE) studies

By Bijsterveld N.R.   Peters R.J.G.   Murphy S.A.   Bernink P.J.L.M.   Tijssen J.G.P.   Cohen M.   TIMI 11B/ESSENCE Study Groups  

Journal of the American College of Cardiology, Vol. 42, Iss. 12, 2003-12 ,pp. : 2083-2089

Elsevier

Access to resources Recommend Favorite

ENOXAPARIN, A LOW-MOLECULAR-WEIGHT HEPARIN SUPPRESSES PROTHROMBIN ACTIVATION MORE EFFECTIVELY THAN UNFRACTIONATED HEPARIN IN PATIENTS TREATED FOR VENOUS THROMBOEMBOLISM

By Grosset A.B.   Spiro T.E.   Beynon J.   Rodgers G.M.  

Thrombosis Research, Vol. 86, Iss. 5, 1997-06 ,pp. : 349-354

Elsevier

Access to resources Recommend Favorite

Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial

By  

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 5, Iss. 5, 2016-05 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment

By Sanderink G.-J.C.M.   Guimart C.G.   Ozoux M.-L.   Jariwala N.U.   Shukla U.A.   Boutouyrie B.X.  

Thrombosis Research, Vol. 105, Iss. 3, 2002-02 ,pp. : 225-231

Elsevier

Access to resources Recommend Favorite

Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: Results of the TIMI 31 trial

By Gibson C.   Zorkun Cafer   Molhoek Peter   Żmudka Krzysztof   Greenberg Mark   Mueller Hiltrud   Wesdorp Jan   Louwerenburg Hans   Niederman Alan   Westenburg Jaap   Bikkina Mahesh   Batty John   Winter Jobst   Murphy Sabina   McCabe Carolyn  

Journal of Thrombosis and Thrombolysis, Vol. 22, Iss. 1, 2006-08 ,pp. : 13-21

Springer Publishing Company

Access to resources Recommend Favorite